Skip to content

AirNexis Therapeutics

7 viewers · 30d

Total raised

$62.0M

+$62.0M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $62.0M
ROUNDS
1
INVESTORS
13
FOUNDED
2024
HQ
Palo Alto, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
7

AI overview

Updated

A clinical-stage biotechnology startup founded in January 2026, focused on developing and commercializing novel therapeutics for respiratory diseases like chronic obstructive pulmonary disease (COPD). The company's business model involves in-licensing late-stage clinical assets and advancing them through global development outside of Greater China. Its lead program is a dual PDE3/4 inhibitor for COPD maintenance treatment.

What sets it apart

The company launched with a significant $200 million Series A financing and a clinical-stage asset, AN01, allowing it to bypass early discovery and focus immediately on late-stage global development. This strategy, combined with an experienced leadership team and strong investor backing, positions it to quickly address unmet needs in the large COPD market.

Funding history

1 round
EquityJan 9, 2026
Form D
+$62.0M$62.0M total

Latest SEC filings

via EDGAR · CIK 0002116194
Form D · Jan 9, 2026View on EDGAR

Products

1 tracked

AN01 (HSK39004)

COPD Therapeutic

AN01 is an inhaled, dual-mechanism phosphodiesterase 3 and 4 (PDE3/4) inhibitor in Phase 2 development. It is intended for the maintenance treatment of COPD. The company holds exclusive global development rights outside of Greater China, having licensed the asset from Haisco Pharmaceutical Group, which previously advanced it through Phase 2 trials in China.

  • Dual mechanism of action that promotes bronchodilation to expand airways and concurrently reduces inflammatory factors.
  • Offered in multiple dosage formats, including an inhalation suspension and an inhalation powder, providing options for patient administration.
  • A clinical-stage asset with existing human safety and efficacy data from prior development in China.

Links

SEC EDGAR filings